To ?he Editor: competent donor lymphocytes and not due to passive transfer of antibodies during marrow transfusion.' Passenger lymphocyte-medi-Minor A B 0 incompatibility, in which donor-derived antibodies ate hemolysis has been described in solid organ transplant recipients are directed against antigens on the recipient's erythrocytes, may treated by cyclosporine? The donor origin of the antibodies has been cause delayed hemolysis of recipient erythrocytes 1 to 2 weeks after confirmed by studies of Ig allotype^.^ We describe the first case of allogeneic bone marrow transplantation (BMT). This phenomenon donor-derived immune hemolysis occumng after allogeneic periphis caused by transient antibody production from passenger immuno-eral blood stem cell transplantation (PBSCT).
BACKGROUND: Lu6 is a high‐incidence antigen of the Lutheran blood group. Examples of anti‐Lu6 are rare and are of uncertain clinical significance.
CASE REPORT: Three patients were encountered in whom anti‐Lu6 was detected on pretransfusion screening. The patients were all Iranian Jews and were not known to be related. In vitro studies to ascertain the potential clinical significance of the antibody using the monocyte monolayer assay (MMA) were negative in two patients. The third patient received a two‐unit transfusion of incompatible Lu6 RBCs with no signs of hemolysis. However, after the transfusion, the MMA and a chemiluminescence test were positive, whereas a chromium survival study was normal. Thus, the antibody may have changed in its clinical significance.
CONCLUSION: Although anti‐Lu6 does not appear to be a clinically significant RBC antibody in all circumstances, transfusion of Lu6 RBCs in patients with anti‐Lu6 should be performed cautiously.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.